Related Experiment Video
Updated: Jul 9, 2026

Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
Published on: March 3, 2023
Expanding access to nicotine replacement therapy through Minnesota's QUITLINE partnership
Barbara A Schillo1, Ann Wendling, Jessie Saul
1ClearWay Minnesota, Minneapolis, MN 55425, USA. bschillo@clearwaymn.org
Background:
Partnerships can expand the reach and effectiveness of quitlines while conserving limited tobacco control dollars.
Objective:
To describe how the addition of free nicotine replacement therapy (NRT) to the "QUITPLAN Helpline" in Minnesota influenced triage and transfer to health plan quitlines and how efforts taken to re-establish balance in the partnership expanded population based access to NRT.
Methods:
NRT provision began in September 2002. Call volumes, transfer rates and ClearWay Minnesota dollars spent serving health plan members were examined from May 2001 through November 2005. The process by which health plan quitlines began providing NRT as a result of the addition of NRT to the QUITPLAN Helpline in September 2002 was explored through interviews with health plan representatives.
Results:
Following the addition of NRT to the QUITPLAN Helpline, the percentage of health plan members transferred to their health plans decreased because callers were resisting transfer to their health plans for telephone counselling that did not include NRT. Transfer rates eventually returned to pre-NRT levels following sequential implementation of scripting changes, transfer requirements and collection of health plan identification numbers. These changes reduced ClearWay Minnesota dollars spent on providing services to insured Minnesotans. Through the partnership, all Minnesotans currently have access to both telephone counselling and NRT either at no or low cost.
Conclusions:
Minnesota's partnership has effectively expanded access to NRT through quitlines. The increased use of partnerships for providing quitline services may be effective in broadening population access while conserving limited tobacco control dollars for those without cessation benefits.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Drug Dependence
CNS Depressants: Alcohol and Nicotine
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment